Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surlorian versus placebo in adults with autosomal dominant RYR1-related myopathy
NL-OMON61033Phase 2Not yet recruiting
- Sponsor
- RyCarma Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Surlorian in ryanodine receptor 1 related myopathy (RYR1-RD), sponsored by RyCarma Therapeutics. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Surlorian
03
Conditions
ryanodine receptor 1 related myopathy (RYR1-RD)
Beyond the preview
Go deeper on NL-OMON61033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61033.